Clinical Trials Directory

Trials / Completed

CompletedNCT01885624

Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
31 (actual)
Sponsor
Theramab LLC · Industry
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess safety and tolerability of ascending dosed of TAB08 after single i.v. infusion to the adult healthy volunteers. Additionally were assessed infusion speed tolerability, pharmacokinetics and pharmacodynamics of TAB08 after single i.v. infusion and to explore TAB mechanism-of-action biomarkers.

Conditions

Interventions

TypeNameDescription
BIOLOGICALTAB08monoclonal antibody

Timeline

Start date
2011-11-01
Primary completion
2013-05-01
Completion
2013-06-01
First posted
2013-06-25
Last updated
2017-02-15

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT01885624. Inclusion in this directory is not an endorsement.

Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers (NCT01885624) · Clinical Trials Directory